V. Ratziu

Epidemiology · 2000–2023

A researcher in the Science corpus: 20 papers; trusts 3 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Epidemiology — 305 citations into it; #2,080 of 2,148 by trust here, #107 by citations

Whom V. Ratziu trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. E. Bugianesi
2. L. Adams
3. Giulio Marchesini
4. B. Neuschwander‐Tetri
5. A. Sanyal
6. Z. Younossi
7. J. Browning
8. A. McCullough
9. S. Harrison
10. N. Chalasani

Who trusts V. Ratziu overall

1. S. Friedman
2. Q. Anstee
3. Hailong Li
4. Z. Younossi
5. N. Chalasani
6. G. Targher
7. J. Clark
8. M. Rinella

Papers from V. Ratziu's perspective

Ordered by how strongly the researchers V. Ratziu trusts endorse each paper. Same corpus, a different order for every researcher.

1. ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (Hepatology)
2. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes (Hepatology)
3. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study (Hepatology)
4. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (Obesity Facts)
5. Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases
6. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The… (Journal of the American College of Cardiology)
7. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. (Gastroenterology)
8. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (Hepatology)
9. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (New England Journal of Medicine)
10. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. (Diabetes)

Their papers

• Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. (2008) — 631 citations
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023) — 2,276 citations
• A multi-society Delphi consensus statement on new fatty liver disease nomenclature. (2023) — 2,621 citations
• Advancing the global public health agenda for NAFLD: a consensus statement (2021) — 631 citations
• NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021) — 1,066 citations
• A new definition for metabolic associated fatty liver disease: an international expert consensus statement. (2020) — 3,051 citations
• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (2020) — 1,488 citations
• Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
• Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) — 1,677 citations
• EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (2016) — 3,531 citations
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016) — 918 citations
• Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) — 799 citations
• TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) — 596 citations
• ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (2011) — 738 citations
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010) — 1,090 citations
• Sampling variability of liver biopsy in nonalcoholic fatty liver disease. (2005) — 2,052 citations
• Viral hepatitis B. (2003) — 1,779 citations
• Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C (2003) — 634 citations
• Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. (2001) — 916 citations
• Liver fibrosis in overweight patients. (2000) — 988 citations